Read more: #PSC #PrimarySclerosingCholangitis To view or add a comment, sign in Today, we announced that the VISTAS study, evaluating volixibat in patients with primary sclerosing cholangitis (PSC), met its primary endpoint, showing statistically significant and clinically meaningful reductions in pruritus
This means the ingredients do not expire (i.e
Once weve established the potential for a lawsuit, we move into the evidence-gathering phase
When switching from semaglutide to tirzepatide, it is best to stop semaglutide and initiate tirzepatide at a low dose, typically 2.5 mg weekly, regardless of the semaglutide dose
Consult your healthcare provider before use
By targeting both, it enhances insulin secretion, slows gastric emptying, and reduces appetite, leading to better glycemic control and weight loss